Evrenzo treatment non-dialysis dependence CKD head-to-head phase 3 clinical non-poor effect on daipotin alpha!

Secondary endpoints are the non-disadvantageal and superiority of layered testsData show that ldL-C reduction in LDL-C in LDL-C (minimum square average (LSM) difference of 0.403 mmol/L; 95% CI: 0.510, -0.296; p-0.01), first intravenous iron (risk ratio of .45; 95% CI:0.26, 0.78;p.00.0.0 04) In terms, Evrenzo is superior to Daipatin alpha, and evrenzo is not inferior to Dabotin in terms of average arterial pressure (LSM difference of 0.372 mmHg; 95% CI: -1.587, 0.842) and the time of occurrence of hypertension (HR:0.83; 95% CI: 0.56, 1.22)In terms of safety, the overall incidence of adverse events (TEAE) during treatment of Evrenzo and Dipotimin alpha is comparable (91.6% vs 92.5%)Non-confirmed analysis of the outcome of the major cardiovascular adverse events (MACE)/MACE plus (MACE plus in-patient unstable angina and inpatient congestive heart failure) showed that HR was estimated to be 0.81 (95% CI: 0.52, 1.25) and 0.90 (95% CI:61, 1.32)Dr Jonathan Barratt, professor of nephrology at the University of Leicester in the, said: "The goal of treating CKD anemia is to improve and stabilize hemoglobin levels, but up to half of ckD anemia patients do not have hemoglobin levels within the recommended target value and often experience symptoms that weaken them and make daily activities challengingThe DOLOMITES study showed that Evrenzo was able to correct and maintain hemoglobin levels for up to 2 years in patients with CKD anemia who were not on dialysis"The DOLOMITES study data adds to a wealth of evidence of Evrenzo's efficacy in adult patients with non-dialysis-dependent anaemia, this time compared to an effective control drug, Daesh," said DrBernhardt G Zeiher, Chief Medical Officer ofAstellasThe study aims to assess Evrenzo's new role in correcting and maintaining hemoglobin levels, strengthening Astellas' commitment to translating innovative science into value to patients and addressing unmet medical needs and increased complications of anemia in CKD patientsrenal anemia is one of the main complications of chronic renal disease (CKD) renal dysfunctionWith the progress of CKD, the prevalence and severity of CKD-related anemia increased graduallyPatients with renal anemia are difficult to correct than conventional anemia, the patients are severely weak and have poor quality of lifeCurrent standard treatments for renal anemia are alternative to erythropoietin (EPO hormone), erythropoietin-generated stimulants (ESA) and intravenous iron injections, subcutaneous injections, elevated hemoglobin (Hb) levels in CKD patients, and improved clinical symptomsEvrenzo's active drug ingredient is roxadustat (rosastata), an oral hypoxic induction factor (HIF) oxyplyse (PH) inhibitor, which increases hemoglobin levels by a mechanism different from the mechanism of erythropoietin (ESA)As an HIF-PH inhibitor, roxadustat activates the body's natural protection response to reduced oxygen levels in the bloodThis response involves regulating a variety of complementary processes, promoting coordinated red blood cell production and increasing blood oxygen carrying capacityRoxadustat was discovered by FibroGen and developed in the United States, China and other markets with AstraZeneca, and in Japan and the European Union with AstellasDecember 2018, roxadustat (Rosasta, commodity name: Erijo) was the first to be approved in China for anemia treatment in patients with chronic kidney disease (CKD) dialysisIn August 2019, the drug was approved in China for the treatment of anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD)As the world's first new drug, roxadustat in China to achieve dialysis and non-dialysis chronic kidney disease anemia patients in a comprehensive application, for the vast number of chronic kidney disease groups in China to bring a new treatment breakthroughin Japan, roxadustat has been approved for treatment of dialysis patients, and treatment of non-dialysis patients has submitted a supplementary applicationIn the United States and Europe, listing applications for roxadustat treatment and non-dialysis patients are under regulatory reviewroxadustat is the world's first small molecule low-molecule hypoxic-induced factor, hIF-PHI, to treat renal anemiaThe physiological action of hypoxic induction factor (HIF) not only increases the expression of erythropoietin, but also increases the expression of erythropoietin receptors and proteins that promote iron absorption and circulationRoxadustat inhibits PH enzymes by simulating ketonesdacids, one of the substrates of oxyplyse (PH), which affects the role of PH enzymes in maintaining the balance of HIF production and degradation rates, thus achieving the goal of correcting anemiaas the world's first HIF-PHI, roxadustat effectively promotes red blood cell production by promoting endogenous erythropoietin production, improving the absorption, utilization, and reduction of ferritin, independent of inflammation on hemoglobin and red blood cell productionRoxadustat has been shown to induce red blood cell productionIn multiple subgroups of patients with chronic kidney disease, roxadustat maintains erythropoietin levels at or near the normal physiological range, thereby increasing the number of red blood cells, while not affecting the inflammatory state, and avoiding intravenous iron supplementationOriginal source: Roxadustat SRoxnon-Denis To Darbepoetin in 3 DOLOMITES Study of The Saatin Non-Dialysis-Dependent Adult Patients with Chronic Kidney Diseaseoriginal title: New drug for renal anemia! Evrenzo (Rosasta) treatment of non-dialysis patients dependent on CKD head-to-head phase III clinical non-poor effect saipin alpha!